Pharmacokinetics and tolerability of probucol after multiple oral administration in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 11, 2011, Pages 688-694

  Jeon, H ^a   Lee, S ^a   Kim, T E ^a   Yoon, S H ^a   Shin, S G ^a   Jang, I J ^a   Yu, K S ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Accumulation index; Multiple administrations; Pharmacokinetics; Probucol; Tolerability

Indexed keywords

PROBUCOL;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GINGIVA ULCER; HEADACHE; HUMAN; HUMAN EXPERIMENT; KOREA; LIMB PAIN; LIQUID CHROMATOGRAPHY; MALE; MORNING DOSAGE; NORMAL HUMAN; NOSE CONGESTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; TANDEM MASS SPECTROMETRY; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; MALE; PROBUCOL;

EID: 80054783487     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201525     Document Type: Article

References (25)

1. Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. Am Heart J. 1984; 107: 680-684. doi:10.1016/0002-8703(84)90315-6 PubMed (Pubitemid 14174196)
2. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 1989; 9: 462-469. doi:10.1161/01.ATV.9.4.462 PubMed (Pubitemid 19184480)
3. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006; 17: 333-336. doi:10.1111/j.1540-8167.2006.00408.x PubMed (Pubitemid 43344951)
4. Heeg JF, Tachizawa H. Plasma levels of probucol in man after single and repeated oral doses (author's transl). Nouv Presse Med. 1980; 9: 2990-2994. PubMed (Pubitemid 10029353)
5. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009; 296: 1183-1194. doi:10.1152/ajpendo.90899.2008 PubMed
6. Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997; 27: 285-292. doi:10.1046/j.1365-2362. 1997.1040657.x PubMed (Pubitemid 27163252)
7. Kim KP, Kim BH, Lim KS, Kim TE, Shin SG, Jang IJ, Yu KS. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers. Clin Ther. 2009; 31: 2098-2106. doi:10.1016/j.clinthera.2009.10.005 PubMed
8. Mao SJ, Yates MT, Parker RA, Chi EM, Jackson RL. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. Arterioscler Thromb. 1991; 11: 1266-1275. doi:10.1161/01.ATV.11.5. 1266 PubMed
9. Mellies MJ, Gartside PS, Glatfelter L, Vink P, Guy G, Schonfeld G, Glueck CJ. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Metabolism. 1980; 29: 956-964. doi:10.1016/0026-0495(80) 90039-6 PubMed (Pubitemid 10014400)
10. Morisaki N, Mori S, Kobayashi J, Ishikawa Y, Shinomiya M, Shirai K, Saito Y, Yoshida S. Effects of long-term treatment with probucol on serum lipoproteins in cases of familial hypercholesterolemia in the elderly. J Am Geriatr Soc. 1990; 38: 15-18. PubMed (Pubitemid 20035766)
11. Ou J, Saku K, Jimi S, Ohta T, Zhang B, Pownall HJ, Shimada Y, Tsujita Y, Arakawa K. Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Biochim Biophys Acta. 1998; 1393: 153-160. PubMed (Pubitemid 28495600)
12. Palin KJ, Wilson CG. The effect of different oils on the absorption of probucol in the rat. J Pharm Pharmacol. 1984; 36: 641-643. doi:10.1111/j.2042- 7158.1984.tb04919.x PubMed (Pubitemid 14068736)
13. Pfuetze KD, Dujovne CA. Probucol. Curr Atheroscler Rep. 2000; 2: 47-57. doi:10.1007/s11883-000-0094-0 PubMed
14. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J. 1996; 131: 1184-1191. doi:10.1016/S0002-8703(96)90095-2 PubMed (Pubitemid 26176999)
15. Sasaki N, Saku K, Moroe K, Zhang B, Hirata K, Liu R, Arakawa K. Long-term administration of probucol and QTc interval prolongation. Artery. 1993; 20: 115-121. PubMed (Pubitemid 23141413)
16. Schwedhelm E, Maas R, Troost R, Böger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet. 2003; 42: 437-459. PubMed doi:10.2165/00003088-200342050-00003
17. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, Witteman JC. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006; 47: 362-367. doi:10.1016/j.jacc.2005.08. 067 PubMed
18. Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P; Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997; 337: 365-372. doi:10.1056/NEJM199708073370601 PubMed (Pubitemid 27328366)
19. Taylor HL. Absorption and excretion studies of the Hypocholesterolemic agent 4, 4′-isopropylidendithio) bis (2, 6-di-t-butylphenol). In-house documents.
20. Troendle G, Guerigian J, Sobel S, Johnson M. Probucol and the QT interval. Lancet. 1982; 319: 1179 doi:10.1016/S0140-6736(82)92240-1 PubMed (Pubitemid 12161486)
21. Turgeon J, Dussault S, Haddad P, Groleau J, Ménard C, Michaud SE, Maingrette F, Rivard A. Probucol and antioxidant vitamins rescue ischemia-induced neovascularization in mice exposed to cigarette smoke: potential role of endothelial progenitor cells. Atherosclerosis. 2010; 208: 342-349. doi:10.1016/j.atherosclerosis.2009.08.007 PubMed
22. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009; 207: 16-23. doi:10.1016/j.atherosclerosis.2009. 04.002 PubMed
23. Zaghloul A, Khattab I, Nada A, Al-Saidan S. Preparation, characterization and optimization of probucol self-emulsified drug delivery system to enhance solubility and dissolution. Pharmazie. 2008; 63: 654-660. PubMed
24. Zhao HL, Houweling AH, Vanstone CA, Jew S, Trautwein EA, Duchateau GS, Jones PJ. Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids. 2008; 43: 1155-1164. doi:10.1007/s11745-008-3241-y PubMed
25. Zhou SX, Zhou Y, Zhang YL, Lei J, Wang JF. Antioxidant probucol attenuates myocardial oxidative stress and collagen expressions in post-myocardial infarction rats. J Cardiovasc Pharmacol. 2009; 54: 154-162. doi:10.1097/FJC.0b013e3181af6d7f PubMed